Patents by Inventor Bruno Gander

Bruno Gander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6596278
    Abstract: An immunological response potentiation process is disclosed for synthetic or genetically engineered antigens having low immunogenicity. The antigen is embedded into biodegradable microparticles, and the antigen-loaded microparticles are dispersed in a biodegradable medium. When parenterally administered, the antigen-loaded microparticles trigger a potentiated antibody, TH-lymphocyte and Tc-lymphocyte response, as compared to an aqueous antigen solution. The extent of immunological potentiation is at least comparable with that attained by Incomplete Freund's adjuvant compositions. Linear B-TH-cell epitopes, linear Tc-cell epitopes, dimers and multimers of those epitopes, and mixtures thereof, are used as low immunogenicity antigens. The microparticles are based on biodegradable biopolymers such as polyester, polyanhydride, and polyorthoester.
    Type: Grant
    Filed: October 11, 1995
    Date of Patent: July 22, 2003
    Assignee: RMF Dictagene S.A.
    Inventors: Bruno Gander, Giampietro Corradin, Ying Men, Claudio Thomasin, Hans Peter Merkle
  • Publication number: 20030125388
    Abstract: The invention concerns compositions that contain 5-aminolevulinic acid or/and derivatives thereof dissolved or dispersed in a non-aqueous liquid. The invention in particular concerns a two-chamber system which contains compositions of 5-aminolevulinic acid and/or derivatives thereof in which the active substances are located in a non-aqueous phase and which are ready-to-use after mixing with an aqueous phase.
    Type: Application
    Filed: October 29, 2002
    Publication date: July 3, 2003
    Inventors: Bruno Gander, Antje Bunke, Gerd Burmeister
  • Publication number: 20020041879
    Abstract: An immunological response potentiation process is disclosed for synthetic or genetically engineered antigens having low immunogenicity. The antigen is embedded into biodegradable microparticles, these antigen-loaded microparticles are dispersed in a biodegradable medium which triggers when it is parenterally administered a potentiated antibody, TH-lymphocyte and TC-lymphocyte response, as compared to an aqueous antigen solution. The extent of immunological potentiation is at least comparable with that attained by IFA compositions. Linear B-TH-cell epitopes, linear TC-cell epitopes, dimers and multimers of said epitopes, as well as their mixtures, are used as low immunogenicity antigens. The microparticles are based on biodegradable biopolymers such as polyester, polyanhydride, polyorthoester. By mixing microparticles with different wettabilities, swellabilities, release and biodegradation times, the most intense and longest immunological potentiation is achieved.
    Type: Application
    Filed: October 11, 1995
    Publication date: April 11, 2002
    Inventors: BRUNO GANDER, GIAMPIETRO CORRADIN, YING MEN, CLAUDIO THOMASIN, HANS P. MERKLE
  • Patent number: 5648096
    Abstract: A method for the production of microcapsules embedded with pharmaceuticals, peptides, proteins, enzymes and vaccines, which uses biodegradable solvents, and microcapsules free of toxic residual solvents is described. The microcapsules are obtained by spraying of a solution, suspension or water-in-oil dispersion of active materials and biodegradable polymers.
    Type: Grant
    Filed: June 22, 1994
    Date of Patent: July 15, 1997
    Assignee: Schwarz Pharma AG
    Inventors: Bruno Gander, Hans Peter Merkle